XFOR - X4 gets FDA approval for Xolremdi for WHIM syndrome
2024-04-29 10:24:20 ET
More on X4 Pharmaceuticals
- X4 Pharmaceuticals: PDUFA Excitement Ahead
- X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript
- X4 Pharmaceuticals GAAP EPS of -$0.10 beats by $0.05
- Seeking Alpha’s Quant Rating on X4 Pharmaceuticals
- Historical earnings data for X4 Pharmaceuticals